Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spermosens ABXSAT:SPERM +4.08% Return-on-Tangible-Equity is -159.40% as of Mar. 2026. Among 191 Medical Diagnostics & Research companies, Spermosens AB ranks worse than 83.77% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Spermosens AB's annualized net income for the quarter that ended in Mar. 2026 was kr-8.70 Mil. Spermosens AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was kr5.46 Mil. Therefore, Spermosens AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -159.40%.
The historical rank and industry rank for Spermosens AB's Return-on-Tangible-Equity or its related term are showing as below:
XSAT:SPERM'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1065.63 Med: -360.03 Max: -103.76
Current: -103.76
During the past 7 years, Spermosens AB's highest Return-on-Tangible-Equity was -103.76%. The lowest was -1,065.63%. And the median was -360.03%.
XSAT:SPERM's Return-on-Tangible-Equity is ranked worse than 83.77% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.07
vs XSAT:SPERM: -103.76
Spermosens AB (XSAT:SPERM) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Spermosens AB Return-on-Tangible-Equity Related Terms
Spermosens AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Spermosens AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:SPERM vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Spermosens AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spermosens AB Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Spermosens AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Spermosens AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -159.40% mean?
Spermosens AB (XSAT:SPERM) has a Return-on-Tangible-Equity of -159.40% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Spermosens AB and its competitors. According to the industry distribution chart, Spermosens AB ranks #160 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 83.8%.
Is Spermosens AB's Return-on-Tangible-Equity too high?
Spermosens AB's current Return-on-Tangible-Equity is -159.40%. Based on the distribution chart, Spermosens AB ranks #160 out of 191 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Spermosens AB's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spermosens AB ranks #160 out of 191 companies for Return-on-Tangible-Equity. This places Spermosens AB in the lower half of its industry. The industry median Return-on-Tangible-Equity is 0.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.07, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Spermosens AB and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spermosens AB's current Return-on-Tangible-Equity is -159.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spermosens AB stock overvalued right now?
Spermosens AB (XSAT:SPERM) has a current Return-on-Tangible-Equity of -159.40%. The current Return-on-Tangible-Equity is -159.40%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Spermosens AB (XSAT:SPERM), the current Return-on-Tangible-Equity is -159.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spermosens AB is developing a revolutionary platform technology for diagnosing male-factor infertility and directing to the right infertility treatment. It is a developer of medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:SPERM has been successfully added to your 
